Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of graft-versus-host disease prophylaxis after unrelated donor stem cell transplantation
2019-002419-24Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2020
- Modality
- Small Molecules, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of antithymocyte globulin, cyclophosphamide, sirolimus, cyclosporine and mycophenolate mofetil in graft-versus-host disease (GVHD) (3 arms), sponsored by University of Birmingham. Primary endpoint: GvHD-free, relapse-free survival. Status: unknown.
02
Drugs
antithymocyte globulincyclophosphamidesirolimuscyclosporinemycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2019-002419-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002419-24.